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Abstract
Background: Human Cytomegalovirus (HCMV) is a ubiquitous herpesvirus affecting approximately 90% of the
world population. HCMV causes disease in immunologically naive and immunosuppressed patients. The prevention,
diagnosis and therapy of HCMV infection are thus crucial to public health. The availability of effective prophylactic
and therapeutic treatments remain a significant challenge and no vaccine is currently available. Here, we sought to
define an epitope-based vaccine against HCMV, eliciting B and T cell responses, from experimentally defined HCMV-
specific epitopes.
Results: We selected 398 and 790 experimentally validated HCMV-specific B and T cell epitopes, respectively, from
available epitope resources and apply a knowledge-based approach in combination with immunoinformatic predictions
to ensemble a universal vaccine against HCMV. The T cell component consists of 6 CD8 and 6 CD4 T cell epitopes that
are conserved among HCMV strains. All CD8 T cell epitopes were reported to induce cytotoxic activity, are derived from
early expressed genes and are predicted to provide population protection coverage over 97%. The CD4 T cell epitopes
are derived from HCMV structural proteins and provide a population protection coverage over 92%. The B cell
component consists of just 3 B cell epitopes from the ectodomain of glycoproteins L and H that are highly flexible and
exposed to the solvent.
Conclusions: We have defined a multiantigenic epitope vaccine ensemble against the HCMV that should elicit T and B
cell responses in the entire population. Importantly, although we arrived to this epitope ensemble with the help of
computational predictions, the actual epitopes are not predicted but are known to be immunogenic.
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Background
Human Cytomegalovirus (HCMV) seroprevalence is 50–
90% in the adult population. HCMV can be transmitted
via saliva, sexual contact, placental transfer, breastfeed-
ing, blood transfusion, solid-organ transplantation or
hematopoietic stem cell transplantation. The main risk
factors for HCMV infection, reactivation and disease are:
immune-naive state, immunosuppressive regimens, organ
transplants and co-infection [1]. The prevalence of
congenital HCMV infection has been estimated between
0.5–0.7% in the US, Canada and Western Europe and
between 1 and 2% in South America, Africa and Asia.
Around 13% of infected infants are symptomatic with a
wide range of phenotypes, including prematurity, intra-
uterine growth retardation, hepatomegaly, splenomegaly,
thrombocytopenia, microcephaly, chorioretinitis, sensori-
neural hearing loss and focal neurologic deficits [2].
HCMV, or human herpesvirus 5, is a beta herpesvirus
consisting of a 235 Kpb double-stranded linear DNA core.
HCMV genome is among the longest and most complex
genomes of all human viruses, due to the diversity of wild-
type strains in intrahost and interhost HCMV populations.
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The HCMV genome is translated in 3 overlapping phases
(IE-immediate early: 0-2 h; E-early: < 24 h; L-late: > 24 h)
giving rise to RNAs and proteins with a structural and/or
a functional role in different stages of the viral cycle [3].
Davidson et al. [4] estimate that the wild-type HCMV gen-
ome carries 164–167 coding mRNAs accounting for one
third of transcription, while 4 large non-coding RNAs
account for 65.1%.
Although HCMV can reside in both, myeloid and lymph-
oid lineages, monocytes are its primary target. HCMV re-
activation and dissemination may occur after infected
monocytes migrate into tissues and differentiate into mac-
rophages since, unlike monocytes, they are permissive for
viral gene expression [5]. Initial viral tethering occurs by en-
gagement of glycoprotein M/N to heparin proteoglycans,
followed by binding of monocyte β1 and β2 integrins and
epidermal growth factor receptor (EGFR). This binding
activates downstream receptor signalling, which prompts
viral entry and increases cellular motility, thus facilitating
viral dissemination [6]. Once primary infection begins,
there is a rapid innate response. Toll-like receptors (TLRs)
interact with viral DNA starting the production of inflam-
matory cytokines, such as type I interferons (IFNs), which
leads to an antiviral state and activates dendritic cells
(DCs), macrophages and natural killer (NK) cells [7].
HCMV-specific adaptive immunity is required for
long-lasting protective immunological memory, which
prevents from reinfection, reactivation, uncontrolled
replication and serious disease. Protection against
HCMV is correlated with high frequencies of CD8 cyto-
toxic T lymphocytes (CTLs) specific for immediate-
early 1 protein (IE-1) and 65 KDa phosphoprotein
(pp65) as well as type 1 CD4 T helper (Th1) cells spe-
cific for glycoprotein B (gB), TLR14 and UL16, which
also exhibit cytotoxic activity [8–11]. Unlike T cells, B
cells recognize solvent-exposed epitopes in target anti-
gens. This recognition promotes B cell activation
resulting in the secretion of antibodies (Abs) with the
same specificity. Some protective anti-HCMV Abs have
been shown to recognize envelope glycoprotein B (gB)
and glycoprotein H (gH) [12].
Despite eliciting strong immune responses, HCMV has
a large evasion armoury that is responsible for the resili-
ence of the virus and its prevalence in the population.
HCMV interferes with cytokine pathways, NK cell acti-
vation and antigen processing and presentation [13]. In
addition, several studies point that numerous cycles of
HCMV reactivation can lead to an early state of immune
senescence, characterized by the decline of immune
responsiveness, as well as the reduction in the levels of
naive cells. This feature could be behind the association
between chronic subclinical infection and long-term
diseases such as atherosclerosis, chronic graft rejection,
autoimmunity and certain neoplasias [14, 15].
Despite much effort, an effective treatment for HCMV
disease remains a significant challenge. The most effective
approach to prevent infection, transmission or reactivation
in immune-naive or immunosuppressed individuals will
be a multifunctional HCMV vaccine [16]. Currently, such
a vaccine is not available. Vaccine development requires
much effort, resource, and knowledge; yet the process can
be facilitated greatly using immunoinformatics and related
computational approaches [17–19]. Such approaches are
particularly relevant for the design of epitope-based
vaccines, which stand out for their safety and selectivity
[20, 21]. The design of epitope ensemble vaccines relies
on sophisticated immunoinformatics tools, often based on
machine learning, able to identify the majority of potential
T and B cell epitopes from pathogen genomes [22, 23].
However, such predictions still require experimental valid-
ation, with only a few potential epitopes actually being
immunogenic, and thus suitable for vaccine design [24].
Here, we designed multi-functional epitope-based
vaccine for HCMV through an approach that combines
legacy experimentation with immunoinformatic predic-
tions [25–31]. The approach uses previously validated
epitopes of proven immunogenicity obtained from pub-
lic databases. A long list of experimentally-determined
T-cell and B-cell epitopes is successively pruned by
applying a series of sequence conservation, structural
and immunological criteria. Subsequently, highly con-
served epitopes meeting the required criteria are com-
bined to minimise epitope number while retaining 90%
or greater population protection coverage [25–31]. Our
putative epitope ensemble vaccine should prove a viable
starting point for the development of an effective vaccine
against HCMV.
Results
HCMV amino acid sequence variability
Compared to other organisms, viruses have a high repli-
cation rate, displaying great sequence variability. This
feature facilitates immune evasion and can hinder the
development of vaccines providing protection to all
strains. Such immune evasion can be better countered
back with vaccines consisting of non-variable epitopes
[20]. We analysed the amino acid sequence variability of
HCMV proteins as a way of identifying non-variable epi-
topes (details in Methods). Briefly, we first clustered all
HCMV protein sequences (50,623) around a reference
HCMV genome (NC_006273), obtaining representative
protein clusters (162) for all but 9 of the ORFs included
in the selected reference HCMV genome. We then pro-
duced multiple sequence alignments (MSAs) and sub-
jected them to sequence variability analysis. We found
that only 601 out of 62,196 residues had a variability
H ≥ 0.5 (a site with H ≤ 0.5 is considered to be con-
served). This extremely low variability is unexpected,
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even for a dsDNA virus, facilitating the selection of con-
served epitopes for vaccine design. After these analyses,
we selected only those epitopes that did not have any
single residue with H ≥ 0.5.
Selection of CD8 T cell epitopes
We retrieved from IEDB (https://www.iedb.org/) 20
experimentally verified HCMV-specific CD8 T cell epi-
topes from 499 available epitopes after the following
search criteria: A) recognition by human subjects
exposed to the virus and B) induction of epitope specific
CD8 T cells with killing activity over cells infected with
HCMV. This type of selection guaranties that CD8 T
cell epitopes are appropriately processed and presented
by both, dendritic cells priming epitope-specific CD8 T
cells and infected target cells. Of those, we discarded any
peptide with variable residues and size out of the 9–11
residue-range as they are unlikely to bind class I human
leukocytes antigen (HLA I) molecules. Thus, we retained
9 conserved CD8 T cell epitopes with a size between 9
and 11 residues that were subjected to HLA I binding
predictions and population protection coverage (PPC),
analyses (details in Methods). We found that just a
single epitope (QYDPVAALF) could reach a PPC that is
at the least of 66.71% (Table 1). We computed PPCs for
5 distinct ethnic groups in the USA populations and
thus the minimum PPC is that reached in the group
with the lowest coverage (details in Methods). The com-
bined minimum PPC of all the peptides is 92.99% while
the PPC for each ethnic group is: 99.76% for Blacks,
96.16% for Caucasians, 98.18% for Hispanics, 92.99% for
Native North Americans and 99.96 for Asians. The average
PPC for the USA population is 97.41% and it can be
reached by the combination of 6 epitopes: QYDPVAALF,
NLVPMVATV, TTVYPPSSTAK, HERNGFTVL, QTVTST
PVQGR, TPRVTGGGAM.
Selection of CD4 T cell epitopes
We obtained from IEDB (https://www.iedb.org/) 291
experimentally validated HCMV-specific CD4 T cell epi-
topes recognized by humans exposed to the HCMV. Of
those, we selected 91 epitopes belonging to structural
proteins for size and conservation analysis. Thus, we
identified 77 conserved epitopes with a size between 9
and 21 amino acids, the usual length of peptides
restricted by class II HLA (HLA II) molecules. These 77
epitopes belonged to pp65 (UL83) and gB (UL55). No
conserved epitopes were identified in other structural
proteins. Although these 77 epitope peptides were unique,
some were largely overlapping. Therefore, we applied a
clustering-based procedure (details in Methods) to identify
shared epitopes defined by overlapping peptides. Thus, we
proceeded with 37 CD4 T cell epitopes, 15 derived upon
clusters, for HLA II binding and PPC analyses. In Table 2
we only report epitopes with PPC ≥ 10%. The maximum
PPC obtained with all peptides was 92.49%. However,
we found that only 6 epitopes from the 65 KDa
phosphoprotein were necessary to achieve the same
PPC: SIYVYALPLKMLNIP, KLFMHVTLGSDVEEDLT
MTR, YQEFFWDANDIYRIF, LPLKMLNIPSINVHH,
CSMENTRATKMQVIG and AGILARNLVPMVATV.
Selection of B cell epitopes
We found 398 experimentally validated HCMV-specific
unique linear B cell epitopes generated during a natural
infection. Of those, we focused on conserved epitopes
mapping onto the ectodomain of envelope antigens so
that they could induce protective Abs recognizing viral
particles. Thus, we found 99 epitopes located in the ecto-
domains of glycoprotein H (UL75), glycoprotein L
(UL115), glycoprotein B (UL55), glycoprotein M (UL100),
glycoprotein UL4 (UL4), glycoprotein UL1 (UL1), TLR10
(IRL10) and TRL12 (IRL12). We clustered these epitopes
Table 1 HLA I binding profiles of conserved and experimentally verified HCMV-specific CTL epitopes
Epitope Antigen
gene
Antigen
accession
a HLA I restriction b Extended HLA I restriction c
PPC
(%)
QYDPVAALF UL83 Q6SW59 A*24:02, A*01:01, C*04:01 A*:01:01, A*24:02, B*15:16, B*38:01, B*39011, B*3909,
B*5801, C*04:01, C*07:02
66.71
NLVPMVATV UL83 Q6SW59 A*02:01, A*02:02, A*02:03, A*02:06, A*02:11,
A*02:12, A*02:16, A*02:19, A*24:02, A*69:01,
A*03, B*07:02
A*02:01, A*02:02, A*02:03, A*02:05, A*02:06, A*02:09, A*02:
14, A*68:02, A*02:12, A*02:16, A*02:19, A*02:11, A*69:01,
A*24:02, B*07:02
58.98
TTVYPPSSTAK UL32 Q6SW99 A*03:01 A*0301, B*15:02, B*15:08, C*07:02 34.47
HERNGFTVL UL83 Q6SW59 B*40:01, B*40:02, B*60 A*2902, B*0702, B*1510, B*40:01, B*40:02 24.21
TPRVTGGGAM UL83 Q6SW59 A*02:01, B*07:02 A*02:01, B*07:02, B*55:02, B*27:06 9.79
CEDVPSGKL UL83 Q6SW59 B*40:01, A*03, B*60 B*38:01, B*40:01 2.78
QTVTSTPVQGR UL32 Q6SW99 A*68:01 A*33:01, A*68:01 1.12
AELEGVWQPA UL83 Q6SW59 B*40:06 A*02:09, B*40:06 0
aExperimental restriction found in IEDB; b Experimental plus predicted HLA I restriction/binding (details in Methods); c PPC was computed independently for 5
ethnic groups in the USA population using EPISOPT [27] and here we report the lowest PPC value
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to identify common overlapping epitopes, finding only
two epitopes from 2 sets of 4 and 7 overlapping epitopes
(see Methods). All remaining 90 epitopes were fragmented
into 9mers overlapping 8 amino acids, sought for conser-
vation and clustered to identify the longest conserved frag-
ment. Thus, we identified 15 conserved epitopes for which
we computed their flexibility and accessibility (Table 3).
Since only one epitope (AFHLLLNTYGR) had a flexi-
bility ≥1.0 and an accessibility ≥48%, determining their
location in highly flexible and solvent-exposed regions
[25], we sought for potential B cell epitopes from avail-
able crystal structures of HCMV envelope proteins
(details in Methods) predicting 2 B cell epitopes, one in
the ectodomains of the gH and another one in the ecto-
domain of the gL, that were also conserved (Table 4).
Discussion
There have been considerable efforts to develop a
vaccine against HCMV, ranging from using attenuated
viruses to various viral subunits [16]. However, there is
currently no effective vaccine against HCMV. Subunit
vaccines based on gB have shown 50% efficacy in
preventing primary infection in young mothers and
transplantation recipients, but they cannot prevent
successive infections nor do they produce long-term
protection [32, 33]. Live recombinant vaccines based on
replication-deficient viral vectors (e.g. poxvirus, adeno-
virus) encoding multiple HCMV-specific epitopes have
also been tested but they were poorly immunogenic and
only after long periods of stimulation and expansion
[34]. In this context, we designed a multi-functional epi-
tope-based vaccine against the HCMV.
The main advantage of the epitope-based formula-
tions is their exquisite selectivity as well as the possibil-
ity of inducing immune responses to subdominant
epitopes and to various antigens at the same time.
Moreover, they have been proposed to be safer than
traditional vaccines [20, 35]. Developing epitope-based
vaccines is bound to the need to identify pathogen-spe-
cific epitopes within the relevant antigens, which, in
spite of the available epitope prediction methods, is
only achieved after laborious and costly experiments
[22]. CD8 T cell epitope prediction methods are widely
regarded as the most accurate and yet only 10% of pre-
dicted T cell epitopes are found to be immunogenic
[36]. To bypass this problem, we formulated an epitope
vaccine ensemble for HCMV through a computer-
assisted approach that feeds on previously identified
Table 2 Predicted HLA II binding profile of conserved and experimentally verified HCMV-specific CD4 T cell epitopes
Epitope Antigen
gene
Antigen
accession
a HLA II restriction b Extended HLA II restriction c PPC
(%)
SIYVYALPLKMLNIP UL83 Q6SW59 DRB1*07, DRB1*15:01 DRB1*01:01, DRB1*03:01, DRB1*07:01, DRB1*11:01,
DRB1*15:01
63.95
KLFMHVTLGSDVEEDLTMTR UL83 Q6SW59 DRB1*03 DRB1*03:01, DRB1*04:05, DQA1*05:01/ DQB1*02:01,
DQA1*05:01/ DQB1*03:01
48.03
LPVADAVIHASGKQMWQARL UL83 Q6SW59 DRB1*03 DRB1*01:01, DQA1*05:01/ DQB1*02:01, DQA1*05:01/
DQB1*03:01
42.11
GPISGHVLKAVFSRG UL83 Q6SW59 HLA class II DRB1*01:01, DQA1*05:01/ DQB1*02:01, DQA1*05:01/
DQB1*03:01
42.11
CSMENTRATKMQVIG UL83 Q6SW59 HLA class II DRB1*07:01, DQA1*01:02/ DQB1*06:02 37.99
FTSHEHFGLLCPKSI UL83 Q6SW59 HLA class II DRB1*01:01, DRB1*07:01, DRB1*09:01, DRB5*01:01 34.02
YQEFFWDANDIYRIF UL83 Q6SW59 DRB1*01 DRB1*04:01, DRB3*01:01, DQA1*01:01/ DQB1*05:01 27.69
RNGFTVLCPKNMIIK UL83 Q6SW59 HLA-DR DRB1*01:01, DRB1*09:01, DRB1*11:01 27.09
RLLQTGIHVRVSQPS UL83 Q6SW59 DRB1*15, DQA1*01:02/
DQB1*06:02
DQA1*01:02/ DQB1*06:02 24.17
LRQYDPVAALFFFDI UL83 Q6SW59 DRB1*07 DRB1*07:01, DRB1*09:01, 24.01
LPLKMLNIPSINVHH UL83 Q6SW59 DRB1*03 DRB1*01:01, DRB1*04:04, DRB1*09:01 21.87
QNLKYQEFFWDANDI UL83 Q6SW59 HLA class II DRB5*01:01, DQA1*01:01/ DQB1*05:01 18.56
EPDVYYTSAFVFPTK UL83 Q6SW59 DRB1*07 DRB1*15:01 18.41
MLDVAFTSHEHFGLL UL83 Q6SW59 HLA class II DRB1*07:01 18.23
SDVEEDLTMTRNPQP UL83 Q6SW59 DRB1*03 DRB1*03:01 17.84
AGILARNLVPMVATV UL83 Q6SW59 DRB1*11, DRB3*02:02 DRB1*01:01, DRB3*02:02 11.53
EHPTFTSQYRIQGKL UL83 Q6SW59 DRB1*11:01 DRB1*11:01 10.54
TSQYRIQGKLEYRHT UL83 Q6SW59 DRB1*04, DRB1*13 DRB1*11:01 10.54
a Experimental restriction found in IEDB; b Experimental plus predicted HLA II restriction/binding (details in Methods); c PPC was computed for 21 different
ethnicities around the world
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epitopes readily available in specialized databases [37–40].
Clearly, the main advantage of this approach is the saving
of time and resources as it depends on experimentally-val-
idated epitopes. We first applied this approach for human
immunodeficiency − 1 virus and hepatitis C virus, consid-
ering only CD8 T cell epitope vaccines [27, 29], later ex-
tending this to influenza A virus considering also CD4 T
cell epitopes [31] and more recently to Epstein-Bar virus
including B cell epitopes [25]. The keystone of this ap-
proach is to select conserved epitopes that are likely to in-
duce protective immune responses (Fig. 1). In the specific
case of HCMV, we selected CD8 T cell epitopes that are
processed and presented both by antigen presenting cells
(APCs) and HCMV infected cells, mediate cytotoxic activ-
ity and are derived from early expressed antigens. Conse-
quently, memory CD8 T cells elicited by these epitopes
will detect and kill infected cells early on avoiding virus
dissemination. For CD4 T cell epitopes, we focused on
epitopes presented by APCs from structural proteins so
that they will provide early and effective help. Similarly,
we only considered B cell epitopes mapping onto the
ectodomain of envelope proteins so that they can elicit
Abs recognizing the entire virus and block infection.
The epitopes obtained from the initial selection steps
were subjected to different analysis for vaccine inclusion.
The final epitope ensemble vaccine that we propose
consists of 6 CD8 T cell epitopes, 6 CD4 T cell epitopes
and 3 B cell epitopes (See Table 5). Conserved T cell
epitopes were included in the ensemble for their ability
to be presented by multiple HLA molecules providing
maximum PPC. Thus, the CD4 and CD8 T cell epitope
components are predicted to elicit responses in at least
90% of the population, regardless of their ethnicity. This
level of response assumes that epitopes shown to be
immunogenic in a specific HLA context will be also
immunogenic in all the other HLA contexts defined by
their HLA binding profile. Likewise, it assumes that anti-
gen processing and appropriated epitope release remain
the same in any HLA context. There is considerable
evidence for these assumptions [19, 29]. However, since
epitope-HLA binding profiles are predicted, they will
need confirmation for further vaccine development.
Conserved B cell epitopes in epitope ensemble vaccine
were selected after flexibility and accessibility criteria
and included one experimental epitope on gH and 2 pre-
dicted epitopes, one on gH and another on gL (Table 5).
Table 4 Predicted conserved B cell epitopes from HCMV envelope proteins
Epitope Antigen gene a Accession number b PDB cFlexibility dAccessibility (%)
TYNSSLRNS UL75 Q6SW67 5VOB: A [11–28] 1.752 48.58
TPEAANSVLLD UL115 F5HCH8 5VOB: B [57–69] 1.397 58.36
aAccession number from UniProtKB database. b Tertiary structure of the antigen (PDB code) with epitope location in square brackets. c Average flexibility of
epitope in arbitrary unit (Fb, Eq. 3).
d Average solvent-exposed accessibility of epitope in percentage (Ab, Eq. 4)
Table 3 Conserved and experimentally verified B cell epitopes from HCMV envelope proteins
Epitope Antigen gene a Accession number b PDB c Flexibility d Accessibility (%)
VSIDDDTPML UL75 Q6SW67 5VOB: A [238–247] 0.131 25.37
TNQYLIKGISYPVST UL75 Q6SW67 5VOB: A [592–606] 0.09 32.63
AFHLLLNTYGR UL75 Q6SW67 5VOB: A [37–47] 1.618 55.08
IFTEHVLGFELVPPS UL115 F5HCH8 5VOB: B [173–187] −0.275 11.71
TANQNPSPPWSKLTYSKPH UL130 F5HCP3 5VOB: D [32–50] 0.104 39.64
WSTLTANQNPSPPWSKLTY UL130 F5HCP3 5VOB: D [28–46] 0.138 33.37
FTYDTLRGYINRALA UL55 F5HB53 5C6T: A [486–500] − 0.644 64.02
LRGYINRALAQIAEA UL55 F5HB53 5C6T: A [491–505] −0.645 68.14
NRALAQIAEAWCVDQ UL55 F5HB53 5C6T: A [496–510] −0.724 63.41
QIAEAWCVDQRRTLE UL55 F5HB53 5C6T: A [501–515] −0.904 56.29
SAILSAIYNKPIAAR UL55 F5HB53 5C6T: A [526–540] −1.187 40.75
SKINPSAILSAIYNK UL55 F5HB53 5C6T: A [521–535] −1.241 46.13
VFKELSKINPSAILS UL55 F5HB53 5C6T: A [516–530] −1.322 38.57
YAQLQFTYDTLRGYI UL55 F5HB53 5C6T: A [481–495] −0.734 53.73
NVTFRGLQNKTEDFL UL4 Q6SWC6 – 0.442 19.39
a Accession number from UniProtKB database. b Tertiary structure of the antigen (PDB code) with epitope location in square brackets. c Average flexibility (Fb, Eq. 3)
of epitope in arbitrary units. d Average relative solvent-exposed accessibility of epitope in percentage (Ab, Eq. 4). The epitopes AFHLLLNTYGR and
WSTLTANQNPSPPWSKLTY, were part of the epitopes AASEALDPHAFHLLLNTYGR and SWSTLTANQNPSPPWSKLTY, respectively. Accessibility and flexibility of
NVTFRGLQNKTEDFL was predicted upon the antigen amino acid sequence as it did not map onto any 3D-structure (details in Methods)
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The criteria of flexibility and accessibility that we applied
were optimized to identify unstructured B cell epitopes
lying in flexible and solvent exposed loop regions of the
corresponding native antigens [25]. Consequently, these
B-epitopes can be used as immunogens isolated from the
antigen, e.g. as peptides, to induce the production of Abs
that are likely cross-reactive with the native antigen [22].
All the epitopes in the proposed epitope ensemble are
highly conserved to avoid or reduce immune evasion
caused by viral genetic drift. Interestingly, we found that
despite HCMV having very low sequence variability (1%
of variable residues) only 40% of the selected T cell
epitopes and 15% of the selected B cell epitopes are con-
served. These results indicate that sequence variability
enables HCMV to escape the immune response, particu-
larly the Ab response. They also highlight the crucial
role of T cell responses in the control of HCMV in
infected individuals.
Our epitope ensemble vaccine is multiantigenic, tar-
geting 4 different HCMV proteins: pp65 (UL83),
150KDa phosphoprotein (pp150, UL32), envelope gL
(UL115) and envelope gH (UL75). There are 2 antigens
represented in the CD8 T cell epitope component (pp65
and pp150) and 2 antigens in B cell epitope component
(gL and gH). However, CD4 T cell component only con-
tains epitopes from the pp65. Arguably, it would have
been better to include epitopes from some other anti-
gens in the CD4 T cell component. However, the
selected CD4 T cell epitopes do provide the maximum
PPC and ought to offer effective help to both CD8 T
cells and B cells.
Three of the targeted antigens (UL83, UL115 and
UL75) have been included in other vaccines currently
undergoing clinical trials, highlighting the importance of
these antigens as components of a HCMV-specific vac-
cine. The viral protein pp65 (UL83) is delivered to
infected cells as a virion component and rapidly moves
to the nucleus where it antagonizes the cellular antiviral
response through the NF-κB pathway [41]. The viral
protein pp150 (UL32) associates with the nuclear viral
capsids before DNA encapsidation and later protects
nucleocapsids along secondary envelopment at the
assembly compartment [42]. gH and gL are part of the
gH/gL/gO trimeric complex and the gH/gL/UL128/
UL130/UL131A pentameric complex which are import-
ant for viral entry into fibroblasts (trimeric complex)
and epithelial and endothelial cells (pentameric complex)
[43]. It has been shown that antibodies targeting gL/gH
can hinder assembly of both complexes blocking HCMV
entry into host cells [43]. Interestingly, the three B cell
epitopes selected in this study are in regions of gL and
gH interacting with proteins of the trimeric and penta-
meric complexes (Fig. 2). Thereby, we speculate that
Abs elicited by these 3 B cell epitopes will block HCMV
entry in fibroblasts and epithelial and endothelial cells.
HCMV has additional proteins that are also important
for entry in other cell types such as gB and the gM/gN
complex that are involved in HCMV infection of
Fig. 1 Mapping of predicted (purple and blue) and experimentally defined (red) B cell epitopes on the tertiary structure of the gH and gL as part
of the pentameric complex UL75/UL115/UL128/UL130/UL131A. B cell epitopes are respresented as sticks over a background of ribbons
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monocytes [43]. It would have been desirable to have
these HCMV envelope proteins represented in the B cell
epitope component of our vaccine. Unfortunately, we
could not identify conserved B cell epitopes meeting our
criteria of flexibility and accessibility in such proteins.
A potential adverse effect of vaccines is that of indu-
cing immune responses cross-reactive with self-antigens.
Thereby, we verified that none of the included epitopes
matched exactly human proteins or human microbiome
proteins. The sequence similarity of all epitopes with
human proteins is less than 80%; only two epitopes have
a similarity over 80% with microbiome proteins. Since
immune recognition is exquisitely specific, it can be
disrupted by single amino acid mutation [44], and it is
unlikely that the epitope ensemble proposed here will
elicit harmful self-immune responses.
Conclusions
We have assembled a HCMV vaccine consisting of 6
CD8 T, 6 CD4 T and 3 B cell epitopes from 4 different
HCMV antigens. The epitopes do not match self pro-
teins, are conserved and all but 2 B cell epitopes are
experimentally verified and reported to be recognized by
humans exposed to HCMV. This epitope ensemble was
built using a knowledge-based, computer assisted ap-
proach aimed at identifying epitopes that are likely to
induce protective adaptive immune responses. Thus, the
T cell epitopes are predicted to provide a PPC over 90%
and include CD8 T cell epitopes mediating cytoxicity
against HCMV infected cells. The B cell epitopes are all
in highly flexible and accessible regions of the ectodo-
main of gH and gL proteins which makes them suitable
for inducing Abs cross-reactive with the relevant native
antigens. Moreover, they are proximally located to re-
gions involved in the assembly of key complexes for viral
entry. Thus, Abs induced by these epitopes could be
neutralizing and block infection.
We have sought to identify optimal epitope components
for making a protective HCMV vaccine, but there remains
a long road ahead prior to deploying a preventive vaccine.
Epitope peptides are known to be poorly immunogenic
and the epitope ensemble will have to be contained within
a formulation capable of inducing potent innate and adap-
tive immune responses. An attractive formulation will be
to encapsulate the T cell epitopes along with appropriated
adjuvant on liposome-based nanoparticles, displaying the
B cell epitopes on the outer surface [45].
Methods
Collection of HCMV-specific immunogenic epitopes and
3D-structures of HCMV envelope proteins
Experimentally confirmed HCMV-specific epitopes were
obtained from IEDB [46]. We only considered epitopes
producing positive assays with humans as the host. In
addition, we applied different search criteria to B and T
cell epitopes. For B cell epitopes, we considered any
Table 5 Epitope ensemble vaccine for HCMV
Epitope Antigen gene Antigen accession BLAST hit human (%) BLAST hit HMP (%) PPC (%)
CD8 T cell epitope vaccine component
QYDPVAALF UL83 Q6SW59 NP_060360.3 (66.67) ETS98202.1 (78.00) 66.71
NLVPMVATV UL83 Q6SW59 AMD82163.1 (66.67) KWZ77571.1 (78.00) 58.98
TTVYPPSSTAK UL32 Q6SW99 CAC15059.1 (63.64) OFS88048.1 (72.73) 34.47
HERNGFTVL UL83 Q6SW59 XP_016879611.1 (77.78) EGG81521.1 (77.78) 24.21
TPRVTGGGAM UL83 Q6SW59 AGP01160.1 (70.00) EJD64485.1 (80.00) 9.79
QTVTSTPVQGR UL32 Q6SW99 NP_005892.1 (63.64) EHY57399.1 (82.00) 1.12
CD4 T cell epitope vaccine component
SIYVYALPLKMLNIP UL83 Q6SW59 XP_006724177.2 (46.67) AEA20835.1 (73.33) 63.95
KLFMHVTLGSDVEEDLTMTR UL83 Q6SW59 EAX02867.1 (45.00) ERJ00718.1 (45.00) 48.03
YQEFFWDANDIYRIF UL83 Q6SW59 EAW98902.1 (46.67) EIJ68880.1 (60.00) 27.69
LPLKMLNIPSINVHH UL83 Q6SW59 EAX02055.1 (46.67) EEU31012.1 (73.33) 21.87
CSMENTRATKMQVIG UL83 Q6SW59 EAW54200.1 (53.33) EGL44246.1 (73.33) 37.99
AGILARNLVPMVATV UL83 Q6SW59 BAC11142.1 (46.67) EFV13316.1 (73.33) 11.53
B cell epitope vaccine component
AFHLLLNTYGR UL75 Q6SW67 EAW77317.1 (63.64) KXA44279.1 (63.64)
*TYNSSLRNS UL75 Q6SW67 AHA56189.1 (78.00) EFE23794.1 (90.00)
*TPEAANSVLLD UL115 F5HCH8 NP_001017403.1 (72.73) OFU98142.1 (72.73)
We show closest blast hits to human Proteins and Human Microbiome Proteins. The B cell epitope component contains one epitope validated experimentally and
2 predicted epitopes (*). PPC of the entire CD8 and CD4 T cell component is 97.41 and 92.49%
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linear peptide from HCMV while we only considered
HCMV-specific T cell epitopes that were elicited in
humans exposed to the HCMV. In addition, for CD8 T
cell epitopes, we restricted the selection to those that
were reported to test positive on 51Cr cytotoxic assays
with cells infected with HCMV (relation between epi-
tope and antigen is source organism).
Multiple sequence alignment of HCMV proteins and
generation of consensus proteins through sequence
variability analysis
We used CD-HIT [47] to cluster HCMV protein sequences
(50,623) – obtained from NCBI taxonomy database (TAX
ID: 10359) [48] and including the open reading frames
(ORFs) of a reference HCMV genome (NC_006273)–,
using an identity threshold of 85%. Subsequently, we se-
lected those clusters containing reference sequences and
produced multiple sequence alignments (MSA) using
MUSCLE [49].
Sequence variability of the MSA was analysed per site/
position using the Shannon Entropy (H) [50], as the vari-
ability metric (Eq. 1).
H ¼ −
XM
i
PiLog2 Pið Þ ð1Þ
where Pi is the fraction of residues of amino acid type i
and M is the number of amino acid types. H ranges from
0 (only one amino acid type is present at that position)
to 4.322 (every amino acid is equally represented in that
position). Following these calculations, we masked in the
reference HCMV proteome (NC_006273) any site with
H ≥ 0.5, thus generating consensus sequences. HCMV
epitopes that matched entirely with the consensus
HCMV sequences were retained for subsequent analysis.
Fig. 2 Knowledge-based selection of experimental epitopes for HCMV vaccine design. Experimental epitopes were obtained form IEDB and
selected to identify those that are more likely to induce protective immunity in humans. CD8 T cell epitopes were identified upon searches that
guarantee that were processed and presented early by APCs (immunogen exposition) and by target cells (mediate cytotoxic activity of cells
infected with HCMV). CD4 T cell epitopes were selected for being recognized by HCMV exposed subjects and belonging to structural proteins, so
that they will provide early effective help. B cell epitopes were also selected for being recognized by HCMV exposed subjects and mapping onto
the ectodomain of envelope proteins so that they can induce neutralizing antibodies
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Simplification of epitope datasets containing overlapping
peptides
We used CD-HIT [47] to identify clusters of overlapping
peptide sequences in the CD4 and B cell epitope datasets.
MSAs generated after the relevant clusters were processed
so that overlapping epitopes were then represented by the
common core defined by the MSA. For CD4 T cell
epitopes, the common core was extended up to a length
15 residues when needed, adding relevant N- and/or C-
terminal residues. No common core longer than 15 resi-
dues was identified for overlapping CD4 T cell epitopes.
Prediction of peptide HLA binding profiles and
computation of population protection coverage
We predicted binding of CD8 T cell epitopes to 55 HLA I
molecules using EPISOPT (http://imed.med.ucm.es/Tools/
episopt.html) [27]. EPISOPT uses profile-motifs to predict
peptide-MHC binding [51, 52] and considers peptides as
HLA binders when their score is within the top 2% percent-
ile. HLA I allele specific profile-motifs in EPISOPT only
predict binding of 9mer peptides, which is the most com-
mon size of peptides found to bind HLA I molecules [53].
For longer peptides, HLA I binding profiles were obtained
evaluating the binding of all 9mer peptides within the lon-
ger peptide. For CD4 T cell epitopes, we predicted peptide
binding to a reference set of 27 HLA II molecules [54] with
IEDB tools (http://tools.iedb.org/mhcii/). The reference set
includes HLA II molecules belonging to HLA-DP, HLA-
DQ and HLA-DR genes and a 5% percentile rank was used
to assess binding. As the prediction method, we selected
“IEDB recommended”. This method provides a consensus
prediction which combines matrix and neural network-
based models, when the relevant predictors are available,
otherwise returning predictions provided by NetMHCIIpan
[55]. For peptides longer than 15 residues, predicted HLA-
II binding profiles corresponded to all 15-mers overlapping
14 amino acids contained in the longer peptide. Epitope
population protection coverage (PPC) was computed with
EPISOPT [27] for CD8 T cell epitopes and with the IEDB
PPC tool for CD4 T cell epitopes (http://tools.iedb.org/
tools/population/iedb_input) [56]. EPISOPT computes the
PPC for 5 distinct ethnic groups prevalent in North Amer-
ica (Black, Caucasian, Hispanic, Asian and Native North
American), accounting for linkage disequilibrium be-
tween HLA I alleles [27], and identifies epitope ensem-
bles reaching a determined PPC. The IEDB PPC tool
does not consider linkage disequilibrium between HLA
II alleles but does include allele frequency for 21 differ-
ent ethnicities around the world [56].
Computation of flexibility and accessibility of B cell
epitopes
The flexibility and accessibility of B cell epitopes was
predicted using the relevant Protein Data Bank (PDB)
files, when available, as described elsewhere [25]. Briefly,
we computed normalized Cα B-factors, ZBi (Eq. 2), after
the PDBs and used them as a measure of flexibility:
ZBi ¼ Bi−μBð Þ∂B ð2Þ
In Eq. 2, Bi is the B factor of the Cα from residue i,
obtained from relevant PDB, μB is the mean of Cα B
factors, and ∂B is the corresponding standard deviation.
Likewise, we used NACCESS [57] to compute residue
relative solvent accessibility (RSA) from the relevant
PDBs.
Subsequently, we used Eq. 3 and 4 to compute an
average flexibility (Fb) and accessibility (Ab), respectively,
for each B cell epitope.
Fb ¼
Pi¼n
i¼1ZBi
n
ð3Þ
Ab ¼
Pi¼n
i¼1RSAi
n
ð4Þ
where n is the total number of residues encompassed
by the B cell epitope.
For B cell epitope sequences in antigens without
solved tertiary structure, we predicted residue RSA and
normalized B values with NetSurfP [58] and profBval
[59], respectively, using as input the entire antigen
sequence. Subsequently, we computed Fb and Ab values
with predicted B and RSA values of the relevant residues
(Eq. 3 and 4). We also used Eq. 3 and 4 for de novo pre-
diction of potential B cell epitopes within selected
HCMV antigens of known tertiary structures. Specific-
ally, we considered as B cell epitopes those fragments
consisting of 9 or more consecutive residues with a Fb ≥
1.0 and an Ab ≥ 48%. Peptides fitting these structural
criteria are found to be located in highly flexible and
solvent-exposed regions of the antigen [25].
Other procedures
We used BLAST searches [60] against the PDB database
subset at NCBI to map B cell epitopes onto 3D-struc-
tures and retrieve the relevant PDBs. We also used
BLAST searches to determine sequence identity between
epitopes and human or human microbiome proteins as
described elsewhere [25]. For these searches, we used
the NCBI non-redundant (NR) collection of human pro-
teins and the human microbiome protein sequences
obtained from the NIH Human Microbiome Project at
NCBI (https://www.ncbi.nlm.nih.gov/bioproject/43021).
We visualized 3D-structures and produced molecular
renderings using the PyMOL Molecular Graphics
System, Version 1.2r3pre, Schrödinger, LLC.
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